Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

Autor: Thijs ten Doesschate, Forecast study team, Wouter van den Bijllaardt, Robert-Jan Hassing, Judith Branger, Suzanne E. Geerlings, Cornelis H. van Werkhoven, Marc J. M. Bonten, Tom Ketels, Ad Koster, Andy I. M. Hoepelman, Cees van Nieuwkoop, Suzan P. van Mens, Akke K. van der Bij, Evert L Koldewijn, S G Kuiper

Publikováno v: Clinical Infectious Diseases, 75(2), 221-229. Oxford University Press
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
FORECAST Study Team 2022, ' Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women : A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial ', Clinical Infectious Diseases, vol. 75, no. 2, pp. 221-229 . https://doi.org/10.1093/cid/ciab934
Clinical infectious diseases, 75(2), 221-229. Oxford University Press

Background We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women. Methods This was a double-blind, randomized, controlled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3776b6d3e69326b816b654f94ee4891c
https://cris.maastrichtuniversity.nl/en/publications/4ec9a699-dc85-41ec-a0d5-154baf6c99ba